Morning Short Course

Genetically Engineered Mouse Models versus Patient-Derived Xenograft Models: Comparing Strengths and Limitations 

Monday, February 10, 2014 | 8:30 - 11:30 am | Moscone North Convention Center | San Fransisco, CA 

The versatile agenda for this course aimed at comparative assessment of contemporary approaches to model cancer in two best predictive murine systems will include the following topics:

  • Design, development and preclinical validation of genetically engineered (GEM) and patient-derived xenograft (PDX) mouse models;
  • Review the current spectrum of available GEM and PDX models outlining annotation practices and benefits vs. shortcomings of two different methodologies as highlighted by specific examples;
  • Analyze current and expected impact of modeling cancer in GEMs and PDXs on in-depth disease analysis and designing therapeutic strategies for unmet need” rare cancer types;
  • Discuss informative capabilities of preclinical models to guide decision making at clinical trial steps of oncology drug evaluation;
  • Describe differential approaches in modeling disease evolution vs. advanced/metastatic disease using GEMs and PDXs in the context of multi-facet implications of murine cancer models for e.g. advanced studies on molecular basis of carcinogenesis, biomarker and imaging modality development and preclinical drug efficacy assessment;
  • Provide examples of available integrated GEM and PDX resources, operational workflows and best practices of exploring murine models for translational and preclinical experimentations


Serguei Kozlov, Ph.D., Principal Scientist, Center for Advanced Pre-Clinical Research, SAIC-Frederick, Inc. 

Byron C. Hann, M.D., Ph.D., Associate Researcher, Manager of Pre-Clinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center 



Back To Short Courses 

Premier Sponsors:  

Bina Technologies




Jackson Laboratory - small logo 


 Precision for Medicine 


Silicon Biosystems

Thomson Reuters-Large